Logo image of BIO

BIO-RAD LABORATORIES-A (BIO) Stock Price, Forecast & Analysis

USA - New York Stock Exchange - NYSE:BIO - US0905722072 - Common Stock

308.13 USD
-5.84 (-1.86%)
Last: 12/12/2025, 8:15:52 PM
308.13 USD
0 (0%)
After Hours: 12/12/2025, 8:15:52 PM

BIO Key Statistics, Chart & Performance

Key Statistics
Market Cap8.31B
Revenue(TTM)2.56B
Net Income(TTM)-675.90M
Shares26.97M
Float18.32M
52 Week High373.69
52 Week Low211.43
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)10.31
PE29.89
Fwd PE29.67
Earnings (Next)02-11 2026-02-11/amc
IPO1980-03-17
Sector
GICS SectorHealth Care
GICS IndustryLife Sciences Tools & Services
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences


BIO short term performance overview.The bars show the price performance of BIO in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 20 30

BIO long term performance overview.The bars show the price performance of BIO in the last 1, 2 and 3 years. 1 year 2 years 3 years -5 -10 -15 -20 -25

The current stock price of BIO is 308.13 USD. In the past month the price decreased by -2.76%. In the past year, price decreased by -8.37%.

BIO-RAD LABORATORIES-A / BIO Daily stock chart

BIO Latest News, Press Relases and Analysis

a month ago - By: Zacks Investment Research - Mentions: SMTI
a month ago - By: Bio-Rad Laboratories, Inc.
2 months ago - By: Zacks Investment Research - Mentions: NVST
4 months ago - By: The Motley Fool

BIO Competitors/Peers

The largest stocks on the US markets in the "Life Sciences Tools & Services" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
TMO THERMO FISHER SCIENTIFIC INC 25.55 215.01B
DHR DANAHER CORP 29.36 159.87B
BRKRP BRUKER CORP - BRKR 6 3/8 09/01/28 174.99 53.17B
A AGILENT TECHNOLOGIES INC 25.03 39.60B
IQV IQVIA HOLDINGS INC 19.11 37.85B
MTD METTLER-TOLEDO INTERNATIONAL 33.31 28.47B
WAT WATERS CORP 30.34 22.94B
ILMN ILLUMINA INC 30.93 20.61B
WST WEST PHARMACEUTICAL SERVICES 37.84 19.25B
MEDP MEDPACE HOLDINGS INC 39.01 15.72B
TEM TEMPUS AI INC N/A 12.56B
RVTY REVVITY INC 20.98 11.39B

About BIO

Company Profile

BIO logo image Bio-Rad Laboratories, Inc. engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. The company is headquartered in Hercules, California and currently employs 7,700 full-time employees. The firm offers a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components. The company operates through two segments: Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables used for biological research, biopharmaceutical production processes, food testing regimes, and science education. Its Clinical Diagnostics segment designs, manufactures, markets and supports test systems, informatics systems, test kits and specialized quality controls that serve clinical laboratories in the global diagnostics market. These products are sold to hospital laboratories, diagnostic reference laboratories, transfusion laboratories, and physician office laboratories.

Company Info

BIO-RAD LABORATORIES-A

1000 Alfred Nobel Dr

Hercules CALIFORNIA 94547 US

CEO: Norman Schwartz

Employees: 7700

BIO Company Website

BIO Investor Relations

Phone: 15107247000

BIO-RAD LABORATORIES-A / BIO FAQ

What does BIO do?

Bio-Rad Laboratories, Inc. engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. The company is headquartered in Hercules, California and currently employs 7,700 full-time employees. The firm offers a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components. The company operates through two segments: Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables used for biological research, biopharmaceutical production processes, food testing regimes, and science education. Its Clinical Diagnostics segment designs, manufactures, markets and supports test systems, informatics systems, test kits and specialized quality controls that serve clinical laboratories in the global diagnostics market. These products are sold to hospital laboratories, diagnostic reference laboratories, transfusion laboratories, and physician office laboratories.


What is the stock price of BIO-RAD LABORATORIES-A today?

The current stock price of BIO is 308.13 USD. The price decreased by -1.86% in the last trading session.


Does BIO stock pay dividends?

BIO does not pay a dividend.


What is the ChartMill technical and fundamental rating of BIO stock?

BIO has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 4 out of 10.


What is the analyst forecast for BIO stock?

10 analysts have analysed BIO and the average price target is 362.1 USD. This implies a price increase of 17.52% is expected in the next year compared to the current price of 308.13.


How is the valuation of BIO-RAD LABORATORIES-A (BIO) based on its PE ratio?

The PE ratio for BIO-RAD LABORATORIES-A (BIO) is 29.89. This is based on the reported non-GAAP earnings per share of 10.31 and the current share price of 308.13 USD.


Would investing in BIO-RAD LABORATORIES-A be a good decision?

This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on BIO.


BIO Technical Analysis

ChartMill assigns a technical rating of 5 / 10 to BIO. When comparing the yearly performance of all stocks, BIO turns out to be only a medium performer in the overall market: it outperformed 48.22% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

BIO Fundamental Analysis

ChartMill assigns a fundamental rating of 4 / 10 to BIO. BIO has an excellent financial health rating, but there are some minor concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

BIO Financial Highlights

Over the last trailing twelve months BIO reported a non-GAAP Earnings per Share(EPS) of 10.31. The EPS decreased by -1.9% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -6.97%
ROE -10.03%
Debt/Equity 0.18
Chartmill High Growth Momentum
EPS Q2Q%12.44%
Sales Q2Q%0.5%
EPS 1Y (TTM)-1.9%
Revenue 1Y (TTM)-0.88%

BIO Forecast & Estimates

10 analysts have analysed BIO and the average price target is 362.1 USD. This implies a price increase of 17.52% is expected in the next year compared to the current price of 308.13.

For the next year, analysts expect an EPS growth of -1.94% and a revenue growth 0.31% for BIO


Analysts
Analysts76
Price Target362.1 (17.52%)
EPS Next Y-1.94%
Revenue Next Year0.31%

BIO Ownership

Ownership
Inst Owners92.44%
Ins Owners8.18%
Short Float %4.74%
Short Ratio4.05